Purple Biotech Exercises Warrants For $2M Gross Proceeds
Purple Biotech Exercises Warrants For $2M Gross Proceeds
Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 5,633,509 American Depositary Shares (ADSs), each representing 10 ordinary shares, having original exercise prices ranging from $1.25 to $20.00 per ADS, originally issued by Purple Biotech in October 2023, June 2020, January 2019 and June 2018, at a reduced exercise price of $0.36 per ADS. The issuance and/or resale of the ADSs issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form F-3 (File Nos. 333-268710, 333-235327 and 333-215037). The offering is expected to close on or about July 2, 2024, subject to satisfaction of customary closing conditions.
世代生物科技有限公司（“紫色生物科技”或“公司”）（纳斯达克/特拉维夫证券交易所：PPBT），一家正在开发首个治疗方案以克服肿瘤免疫逃避和药物抵抗的临床前公司，今天宣布，已与具体协议达成一致，行使某些现有认股权证，购买5,633,509美国存托股票（ADS），每股代表10股普通股，最初的行使价格范围为每股1.25-20.00美元，于2023年10月、2020年6月、2019年1月和2018年6月由紫色生物科技发行，以降低的行使价格每ADS 0.36美元行使。ADS的发行和/或再销售，按照相关法规对于有效注册的申明书所陈述，而此次发行预计于2024年7月2日左右关闭，须满足惯常的交割条件。
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
H.C.Wainwright & Co.将担任本次定向增发的独家配售代理。